Investors Back iOmx’s Focus On Tumor Immune Evasion

Developing Anti-Immune Evasion Platform

 
• By Andrew McConaghie
  
Euro symbol, Frankfurt
The consortium's funding of €65m will see iOmx's lead candidate through its Phase I development.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip